(R)-(+)-N-[1-(1-萘)乙基]琥珀酰胺酸 | 78681-09-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: (R)-(+)-N-[1-(1-萘)乙基]琥珀酰胺酸
• 英文名称: (R)-(+)-N-[1-(1-Naphthyl)ethyl]succinamic acid
• 英文别名: 4-[[(1R)-1-naphthalen-1-ylethyl]amino]-4-oxobutanoic acid
• CAS: 78681-09-1
• 化学式: C₁₆H₁₇NO₃
• 分子量: 271.31
• InChiKey: AUSXHLAOQYCBAR-LLVKDONJSA-N

物化性质

• 熔点：
  157-159 °C(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2924299090

文献信息

• SUBSTITUTED BENZHYDRYLETHERS
  申请人：Gant Thomas G.

  公开号：US20090203763A1

  公开（公告）日：2009-08-13

  Disclosed herein are substituted benzhydrylethers of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of their use thereof.

  本文揭示了式I的取代苯基乙醚，其制备方法，药物组合物以及它们的使用方法。
• SUBSTITUTED PHENETHYLAMINES
  申请人：Gant Thomas G.

  公开号：US20080300316A1

  公开（公告）日：2008-12-04

  Disclosed herein are substituted phenethylamine alpha adrenergic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本文公开了Formula I的取代苯乙胺α肾上腺素受体调节剂，其制备方法，药物组合物以及使用方法。
• Crystalline forms of a BACE inhibitor, compositions, and their use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10017505B2

  公开（公告）日：2018-07-10

  The present invention provides four crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pathology and/or a symptom or symptoms thereof. Non-limiting examples of such Aβ pathologies, including Alzheimer's disease, are disclosed herein.

  本发明提供了四种韦鲁贝斯特的结晶形式及其药学上可接受的组合物，其中每一种都可用于治疗、预防、改善和/或延迟Aβ病理学和/或其症状的发作。本文公开了包括阿尔茨海默病在内的此类 Aβ 病理学的非限制性实例。
• SALTS OF PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1091958A1

  公开（公告）日：2001-04-18
• NOVEL CRYSTALLINE FORMS OF A BACE INHIBITOR, COMPOSITIONS, AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170226098A1

  公开（公告）日：2017-08-10

  The present invention provides a novel synthesis of verubecestat, and two novel crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pathology and/or a symptom or symptoms thereof. Non-limiting examples of such Aβ pathologies, including Alzheimer's disease, are disclosed herein.